FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

@article{Stirewalt2001FLT3RA,
  title={FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.},
  author={Derek L Stirewalt and Kenneth J. Kopecky and Soheil Meshinchi and Frederick R. Appelbaum and Marilyn L. Slovak and Cheryl Willman and Jerald P Radich},
  journal={Blood},
  year={2001},
  volume={97 11},
  pages={
          3589-95
        }
}
The prevalence and significance of genetic abnormalities in older patients with acute myeloid leukemia (AML) are unknown. Polymerase chain reactions and single-stranded conformational polymorphism analyses were used to examine 140 elderly AML patients enrolled in the Southwest Oncology Group study 9031 for FLT3, RAS, and TP53 mutations, which were found in 34%, 19%, and 9% of patients, respectively. All but one of the FLT3 (46 of 47) mutations were internal tandem duplications (ITDs) within… 
FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance
TLDR
It is suggested that FLT3 mutations are not common in Saudi ALL and do not affect clinical outcome.
RAS, FLT3, and TP53 mutations in therapy‐related myeloid malignancies with abnormalities of chromosomes 5 and 7
Oncogenic mutations in the KRAS2, NRAS, or FLT3 gene are detected in more than 50% of patients with de novo acute myeloid leukemia (AML). RAS mutations are also prevalent in de novo myelodysplastic
Clinical characteristics and prognostic implications of NPM 1 mutations in acute myeloid leukemia
TLDR
The results suggest that the N PM1 mutation is not necessarily an early event during leukemogenesis or that leukemia clones with NPM1 mutations are sensitive to chemotherapy.
RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group
TLDR
The occurrence of clinical events at relatively late period should be monitored for in AML patients with mutations in RAS, as the presence of RAS mutation was related to late relapse.
Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
TLDR
This study confirms previous reports that poor PS and the presence of a complex karyotype are associated with a decreased OS and suggests a possible trend toward worse OS among patients with SNP P72R.
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.
TLDR
RAS mutation did not influence clinical outcome (overall/disease-free survival, complete remission, relapse rate) either for the entire cohort or within cytogenetic risk groups.
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.
TLDR
The results suggest that the N PM1 mutation is not necessarily an early event during leukemogenesis or that leukemia clones with NPM1 mutations are sensitive to chemotherapy.
FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
TLDR
A high frequency of FLT3 mutations is confirmed in APL and in adult AML without recurrent cytogenetic translocations and they were not found as independent prognostic factors although associated with several adverse features at diagnosis.
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group
TLDR
The presence of FLT3-ITD was associated with high white blood cell count, high Sanz index, M3-variant subtype, and V/S PML-RARα isoforms, and the feature, which has been also reported in patients with AML in general, is suggestive of an underlying genetic instability in FLT2-ITd patients, leading to the acquisition of additional unknown bad-prognosis gene mutations at relapse.
Characteristics and Prognosis of Adult Acute Myeloid Leukemia with Internal Tandem Duplication in the FLT3 Gene.
TLDR
The data confirm that FLT3/ITD mutations represent a common alteration in adult acute myeloid leukemia, mainly with normal karyotype and de novo acute myELoid leukemia (75%), as compared to secondary acuteMyeloids leukemia (25%) (p<0.001).
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
TLDR
The FLT3 gene mutation, whose presence is detectable only by genomic polymerase chain reaction amplification and gel electrophoresis, might serve as an important molecular marker to predict the prognosis of patients with AML.
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance.
TLDR
A comparison of patients with and without N-ras mutations showed no statistically significant differences in pretreatment clinical variables, response to induction therapy, or survival, except for a possibly higher percentage of FAB M4 subtypes in patients with the N-ra mutation.
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
TLDR
Findings counter the prevailing bias that oncogene mutations lead to more aggressive behavior in human malignancies and suggest a longer survival in ras-positive patients.
p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies
TLDR
P53 mutations could induce drug resistance, at least in part, by interfering with normal apoptotic pathways in tumor cells, and are a strong prognostic indicator of response to chemotherapy and survival in AML, MDS, and CLL.
Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
TLDR
Data show that the Flt3/ITD represents an important diagnostic marker for patient prognosis, and that the presence of these mutations is associated with altered proliferative ability of progenitors in vivo and in vitro.
Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia.
TLDR
FLT3/ITD was observed in 11% of childhood AML and identified to be associated with poor prognosis and a large prospective study with uniform treatment is necessary to confirm the results.
P53 gene mutations in acute myeloid leukemia with 17p monosomy.
TLDR
The fact that P53 gene mutations occurred more often in patients with 17p monosomy seems to support the "recessive" model of tumor suppressive activity of the P53 genes rather than the "dominant" model, in which alteration of only one allele is sufficient for the development of malignancy.
Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia
TLDR
The results suggest that the tandem duplication in the jm domain of the FLT3 gene is not a frequent phenomenon but might be a factor of poor prognosis in childhood patients with AML.
Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
TLDR
The fact that the accumulation of genetic events, including FLT3 duplication, correlates with leukemic transformation from antecedent myelodysplasia and with subsequent disease progression is uncovered.
P73 mutations and expression in adult de novo acute myelogenous leukemia
TLDR
It is suggested that functional p73 mutations in exons 4, 6 and 7 do not occur in most de novo acute myelogenous leukemia patients, and biallelic expression of p73 occurs in normal bone marrows, some AML samples, and specific cell lines.
...
1
2
3
4
5
...